Ekso Bionics (EKSO) Announces $10 Million Bought Deal Offering Of Common Stock

Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 975,610 shares of common stock of Ekso Bionics, at a price to the public of $10.25 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about February 11, 2021, subject to the satisfaction of customary closing conditions.

H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.

Ekso Bionics also has granted to the underwriter a 30-day option to purchase up to an additional 146,341 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to Ekso Bionics, before deducting underwriting discounts and commissions and offering expenses and assuming no exercise of the underwriter’s option to purchase additional common stock, are expected to be approximately $10.0 million.

Ekso Bionics intends to use the net proceeds from the offering for working capital and other general corporate purposes, which may include repayment of debt, acquisitions and other business opportunities.

You May Also Be Interested In

• Cyngn Inc (CYN) Announces Pricing of $5.0 Million Firm Commitment Public Offering of Common Stock
• Flora Growth Corp (FLGC) Files for 2.14M Share Offering by Selling Stockholders
• Mega Matrix Corp (MPU) Files $3.19M Mixed Shelf